Moody's Investors Service commented that lender consent received by Valeant Pharmaceuticals International, Inc. (NYSE: VRX) related to its senior secured credit facilities is a positive development. There are no changes to Valeant's ratings including the B2 Corporate Family Rating, the Caa1-PD Probability of Default Rating, the Ba2 senior secured rating or the B3 senior unsecured rating at this time. These ratings remain under review for downgrade.